Our vastly experienced team leads the way in life sciences patents




Partners/IP Directors




Technical Assistants


Offices in Europe

There has rarely been a more exciting time to be involved in Life Sciences. This is a time when genetic material can be edited with precision; when the power of the immune system is being harnessed to cure disease; and when bioinformatics and big data open the door for treatments that are truly bespoke for each person. We are proud to offer IP support to innovator companies across this rapidly evolving field.

Our large and vastly experienced team leads the way in life sciences patents. From therapeutics to medical devices, genetic engineering and diagnostics, we cover every aspect. We have been working to protect these inventions since the earliest days of the biotechnology revolution, and we have been shaping IP law in this area since the very beginning. We combine our years of experience with creative, fresh thinking, to design IP strategies that will work in a changing world.

Mewburn Ellis is consistently regarded as a leading choice for IP protection among the world’s top biopharmaceutical companies.  We have deep experience of working to protect high-profile biologics. IP specialists in the team defended patents for half of the top ten selling biologic drugs in 2020, with annual sales for these drugs amounting to over $40 billion.

We are also proud to support many large and small pharma company clients. The Mewburn team includes pharmaceuticals IP specialists who have taken small molecule therapies from first patent draft to worldwide launch, with deep understanding of where real value can be added.

Life Sciences innovation focus

telescope oxblood icon - life sciences

Pharma & Biologics

See More
telescope oxblood icon - life sciences

Nucleic Acids & Molecular Biology

See More
telescope oxblood icon - life sciences

Diagnostics & Precision Medicine

See More
telescope oxblood icon - life sciences

Industrial & Agricultural Biotech

See More

Life Sciences patent specialists

We have long been at the forefront of developing EPO practice in the life sciences field.  For instance, we’ve helped to secure recognition of the patentability of therapeutic treatments based on new diagnostic regimens, new technical effects and new patient subgroups. These influential decisions have helped our clients to protect their investment throughout the drug life cycle.

Our Life Sciences patent team is distinguished by its large number of highly experienced attorneys. Some firms can offer one or two leading figures, we have many. We have an excellent reputation for opposition and appeal work before the EPO and we have many partners who are highly active in this area. This enables us to give each case the attention it requires, and contributes to our enviable success rate.

We also have a strong track record in nurturing inventions arising from universities and research organisations. We have provided the IP foundation on which numerous biotechnology start-up & spin-out companies have been built, and we are proud to have supported many companies through to successful IPO, acquisition or expansion.

Of course, a strong IP strategy in life sciences is about much more than just patents.  For some clients we operate as a surrogate for an in-house IP group, dialling up and down the support according to business needs – covering everything from due diligences, in/out-licensing, drafting & patent portfolio building, freedom-to-operate support and industry-specific strategic advice.

As one of the largest IP specialist firms in Europe, Mewburn Ellis can offer a wealth of relevant expertise, from trade mark protection to Plant Variety Rights (PVRs).

Our legal services team is distinguished by a strong technical background in life science and considerable experience in dealing with regulatory issues, clinical trial practice, and IP exploitation in the this sector. Our Extensions and Exclusivity team includes experienced IP counsel who previously specialised in this area while working in-house for a global pharmaceutical company. Our team regularly supports clients on strategic commercial exclusivity analysis for their products – taking account of the patent, regulatory and real-world factors in order to guide extensions strategy, often before progressing on to the SPC and PTE filings themselves.


Simon Kiddle Feb-21

Talk to our Life Sciences IP experts

Whatever your location or size we have someone who understands your technology and can work with you to achieve your IP goals. Flexible in the way we work, we vary our input based on budgets and commercial objectives, building bespoke teams designed to meet your specific needs.

Not sure who to talk to? Please get in touch and I'll be happy to help.

Simon Kiddle, Head of Life Sciences


What our clients say about our Life Science team

“The consistency provided by the team at Mewburn Ellis since 2000 has been critical for the development of our successful IP strategy."


WisTa Laboratories Ltd

"Simon Kiddle is cleantech guru, with the ability to craft spotless patents and defend the least promising EPO cases with remarkable success."


Legal Directories

"Seán Walton is the guy you pick if you want quality."


Legal Directory

"Simon Kremer's 'silky' life sciences prosecution skills that allow him to work wonders on EPO judges."


Legal Directory

Law & Practice Library


Veriviva strarbis vita, senaticumderunu statior terobse nenatuastuus essis rena, quam, perfirte, sesessis, nos, quo vicavo

Learn More


Veriviva strarbis vita, senaticum derunu statior terobse nenatuastuus essis rena, quam, perfirte, sesessis, nos, quo vicavo

Learn More


Veriviva strarbis vita, senaticum derunu statior terobse nenatuastuus essis rena, quam, perfirte, sesessis, nos, quo vicavo

Learn More

Latest News & Insights

Forward Magazines Overlapping 8

Mewburn Ellis


Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.